New Data and Guidelines in Lipids for Therapeutic Selection and Patient Care Optimization

New Data and Guidelines in Lipids for Therapeutic Selection and Patient Care Optimization is organized by Prime Education LLC. 

Dates: 
Release Date: December 31, 2019
Expiration Date: December 30, 2020

Accreditation:
• 1.0 CME/CE for Physicians (ACCME)
• 1.0 CME/CE for Physician Assistants (AAPA)
• 1.0 CME/CE for Nurse Practitioners (AANP)
• 1.0 CPE for Pharmacists (ACPE + NABP)
• 1.0 CNE for Nurses (ANCC)
• 1.0 CE for Case Managers (CCM, pre-approved)

Activity Overview:
Emerging clinical and cost-effectiveness data for PCSK9 inhibitors have created a need to integrate these therapies into the treatment of patients with hyperlipidemia.

Tune into this engaging webcast, where cardiology and pharmacoeconomic experts discuss these findings and share their insights on the implications of this new evidence for managing patients at high risk for atherosclerotic cardiovascular disease. Using challenging case studies, expert faculty will discuss and apply key takeaways for improved outcomes in patients with hyperlipidemia.

Learning Objectives:
• Apply evidence from cardiovascular outcomes trials (CVOTs) on LDL-cholesterol lowering therapies to make effective individualized treatment decisions for patients with hypercholesterolemia
• Evaluate new guidelines for the treatment of dyslipidemia and use of non-statin therapies
• Improve alignment of treatment practice patterns with evidence-based FL guidelines
• Assess the pharmacoeconomics of lipid-lowering therapies based on latest CVOTs
• Implement medication management strategies to promote appropriate use of PCSK9 inhibitors and to promote adherence

Additional details will be posted as soon as information is available.